SG11202000077RA - Methods of treating behavior alterations - Google Patents
Methods of treating behavior alterationsInfo
- Publication number
- SG11202000077RA SG11202000077RA SG11202000077RA SG11202000077RA SG11202000077RA SG 11202000077R A SG11202000077R A SG 11202000077RA SG 11202000077R A SG11202000077R A SG 11202000077RA SG 11202000077R A SG11202000077R A SG 11202000077RA SG 11202000077R A SG11202000077R A SG 11202000077RA
- Authority
- SG
- Singapore
- Prior art keywords
- llobregat
- ferran
- cornelia
- sant
- international
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau omit omoioninim Imo oimIE (43) International Publication Date 07 February 2019 (07.02.2019) (10) International Publication Number WO 2019/025588 Al WIPO I PCT (51) International Patent Classification: A61K 31/44 (2006.01) A61P 25/28 (2006.01) A61P 25/00 (2006.01) A61P 25/18 (2006.01) A61P 25/24 (2006.01) A61P 25/30 (2006.01) A61P 25/16 (2006.01) A61P 25/08 (2006.01) A61P 25/14 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 17382544.9 03 August 2017 (03.08.2017) 17382545.6 03 August 2017 (03.08.2017) 18382299.8 30 April 2018 (30.04.2018) Published: — with international search report (Art. 21(3)) PCT/EP2018/071120 03 August 2018 (03.08.2018) English English EP EP EP (71) Applicant: ORYZON GENOMICS, S.A. [ES/ES]; Car- rera de San Jeronimo 15, 2a planta, 28014 Madrid (ES). = (72) Inventors: MAES, Tamara; Oryzon Genomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). ROTTLANT POZO, David; Oryzon Genomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). GRISAN FERRE, Christian; Oryzon Genomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). PALLAS LLIBERIA, Meree; Oryzon Genomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). NADAL ALEMANY, Roser; Oryzon Ge- nomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). ARMARIO GARCIA, Antonio; Oryzon Genomics, S.A., Sant Ferran 74, 08940 Cornelia de Llobregat (ES). (74) Agent: OSWIN RIDDERBUSCH, VOSSIUS & PART- NER; Patentanwalte Rechtsanwalte mbB, SiebertstraBe 3, 81675 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 1-1 O \" (57) : Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)- 2-(4- 0 (benzyloxy)phenyi)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine. (54) Title: METHODS OF TREATING BEHAVIOR ALTERATIONS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382544 | 2017-08-03 | ||
EP17382545 | 2017-08-03 | ||
EP18382299 | 2018-04-30 | ||
PCT/EP2018/071120 WO2019025588A1 (en) | 2017-08-03 | 2018-08-03 | Methods of treating behavior alterations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000077RA true SG11202000077RA (en) | 2020-02-27 |
Family
ID=63077881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000077RA SG11202000077RA (en) | 2017-08-03 | 2018-08-03 | Methods of treating behavior alterations |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200323828A1 (en) |
EP (1) | EP3661510A1 (en) |
JP (2) | JP2020529995A (en) |
KR (1) | KR20200036920A (en) |
CN (1) | CN110996949A (en) |
AU (1) | AU2018309372A1 (en) |
BR (1) | BR112020000827A2 (en) |
CA (1) | CA3071804A1 (en) |
IL (1) | IL272092A (en) |
MX (2) | MX2020001323A (en) |
PH (1) | PH12020500211A1 (en) |
SG (1) | SG11202000077RA (en) |
WO (1) | WO2019025588A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017157813A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
US20220151998A1 (en) * | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
JP2022526755A (en) * | 2019-03-20 | 2022-05-26 | オリソン ヘノミクス,ソシエダ アノニマ | Treatment of Attention Deficit Hyperactivity Disorder Using KDM1A Inhibitors such as Compound Bafidemstat |
CN114615979A (en) * | 2019-09-03 | 2022-06-10 | 奥莱松基因组股份有限公司 | Valfelast for the treatment of autism spectrum disorders |
CN114502561B (en) * | 2019-09-29 | 2023-12-26 | 南昌弘益药业有限公司 | LSD1 inhibitors |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
WO2007021839A2 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
JP2010523685A (en) | 2007-04-13 | 2010-07-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Lysine-specific demethylase inhibitor |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
JPWO2010143582A1 (en) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | Phenylcyclopropylamine derivatives and LSD1 inhibitors |
WO2011022489A2 (en) | 2009-08-18 | 2011-02-24 | The Johns Hopkins University | (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
CN102947265B (en) | 2010-04-19 | 2015-07-29 | 奥瑞泽恩基因组学股份有限公司 | Methionin specific demethylase-1 inhibitor and application thereof |
EP2560949B1 (en) | 2010-04-20 | 2015-12-02 | Università degli Studi di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
WO2012013728A1 (en) * | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
MY165620A (en) | 2011-03-25 | 2018-04-18 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
AP2014007488A0 (en) | 2011-08-09 | 2014-03-31 | Takeda Pharmaceutical | Cyclopropaneamine compound |
US8987335B2 (en) | 2011-08-15 | 2015-03-24 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
RS58475B1 (en) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
JP6325449B2 (en) | 2012-10-12 | 2018-05-16 | 武田薬品工業株式会社 | Cyclopropanamine compounds and uses thereof |
JP6238908B2 (en) | 2012-11-28 | 2017-11-29 | 京都府公立大学法人 | LSD1 selective inhibitor having lysine structure |
EP2925307B1 (en) | 2012-11-30 | 2020-10-28 | McCord, Darlene E. | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CN103054869A (en) | 2013-01-18 | 2013-04-24 | 郑州大学 | Application of amino dithio formic ester compound with triazolyl in preparing medicine taking LSD1 (Lysine Specificity Demethylase 1) as target |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
WO2014205213A1 (en) | 2013-06-19 | 2014-12-24 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
CN103319466B (en) | 2013-07-04 | 2016-03-16 | 郑州大学 | Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof |
CN105592888A (en) | 2013-08-06 | 2016-05-18 | 伊美格生物科学公司 | Kdm1a inhibitors for the treatment of disease |
US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
US9556170B2 (en) | 2013-08-30 | 2017-01-31 | University Of Utah Research Foundation | Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors |
CA2933480C (en) | 2013-12-11 | 2022-08-23 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
US10118903B2 (en) | 2014-02-07 | 2018-11-06 | Musc Foundation For Research Development | Aminotriazole-based KDM1A inhibitors as epigenetic modulators |
HUE045725T2 (en) | 2014-02-13 | 2020-01-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2672797T3 (en) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2760261T3 (en) | 2014-02-13 | 2020-05-13 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
CA2941716A1 (en) | 2014-03-07 | 2015-09-11 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
CN103893163B (en) | 2014-03-28 | 2016-02-03 | 中国药科大学 | The application of 2-([1,1 '-biphenyl]-4-base) 2-oxoethyl 4-((the chloro-4-aminomethyl phenyl of 3-) is amino)-4-oxobutanoic acid esters in preparation LSD1 inhibitor medicaments |
CN106459024B (en) | 2014-04-11 | 2019-11-05 | 武田药品工业株式会社 | Cyclopropyl amine compounds and application thereof |
CN103961340B (en) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | A kind of LSD1 inhibitor and its application |
PE20161438A1 (en) | 2014-05-01 | 2017-01-18 | Celgene Quanticel Res Inc | DESMETILASE INHIBITORS 1 SPECIFIC TO LYSINE |
EP3148974B1 (en) | 2014-05-30 | 2018-09-26 | Istituto Europeo di Oncologia S.r.l. | Cyclopropylamine compounds as histone demethylase inhibitors |
MX2017000179A (en) | 2014-06-27 | 2017-05-01 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1. |
CN104119280B (en) | 2014-06-27 | 2016-03-16 | 郑州大学 | Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application |
PT3164380T (en) | 2014-07-03 | 2022-03-02 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
CA2954060A1 (en) | 2014-07-03 | 2016-01-07 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
BR112017004334A2 (en) | 2014-09-05 | 2018-08-07 | Celgene Quanticel Res Inc | lysine-1 specific demethylase inhibitors. |
EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
EP3250552B1 (en) | 2015-01-30 | 2019-03-27 | Genentech, Inc. | Therapeutic compounds and uses thereof |
JP6727216B2 (en) | 2015-02-12 | 2020-07-22 | イマーゴ バイオサイエンシーズ インコーポレイテッド | KDM1A inhibitors for the treatment of diseases |
CN106146361A (en) | 2015-03-16 | 2016-11-23 | 四川大学 | Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use |
MX2017012699A (en) | 2015-04-03 | 2018-02-09 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors. |
CN106045862B (en) | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | Cyclopropyl amine spiral shell (miscellaneous) cycle compound, its pharmaceutical composition and application |
WO2016172496A1 (en) | 2015-04-23 | 2016-10-27 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
US20170001970A1 (en) | 2015-07-02 | 2017-01-05 | University Of Utah Research Foundation | Substituted benzohydrazide analogs as histone demethylase inhibitors |
KR20180051523A (en) | 2015-08-12 | 2018-05-16 | 인사이트 코포레이션 | Salt of LSD1 inhibitor |
EP3371152B1 (en) | 2015-11-05 | 2020-12-23 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
JP6510068B2 (en) | 2015-11-27 | 2019-05-08 | 大鵬薬品工業株式会社 | Novel biphenyl compound or salt thereof |
WO2017109061A1 (en) | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
WO2017116558A1 (en) | 2015-12-29 | 2017-07-06 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
WO2017149463A1 (en) | 2016-03-01 | 2017-09-08 | Novartis Ag | Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors |
CN107200706A (en) | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | Cyclopropylamine class compound of one class fluorine substitution and preparation method thereof, pharmaceutical composition and purposes |
US20170283397A1 (en) | 2016-03-31 | 2017-10-05 | University Of Utah Research Foundation | Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors |
CN109153636B (en) | 2016-05-09 | 2021-10-22 | 朱比连特埃皮科尔有限责任公司 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors |
EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
CN107513068A (en) | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | A kind of new compound and its preparation and application with FGFR inhibitory activity |
CN106478639B (en) | 2016-09-05 | 2018-09-18 | 郑州大学 | LSD1 inhibitor, preparation method and the application of 1,2,4-triazole of pyrimido |
CN106432248B (en) | 2016-09-27 | 2018-11-27 | 郑州大学 | The LSD1 of triazole containing pyrimido inhibitor, preparation method and application |
HRP20231369T1 (en) | 2016-10-26 | 2024-02-16 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and medical uses thereof |
WO2018081342A1 (en) | 2016-10-26 | 2018-05-03 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
CN106831489B (en) | 2017-03-23 | 2018-04-17 | 郑州大学 | Tranylcypromine acylhydrazone, preparation method and applications |
CN106928235A (en) | 2017-05-03 | 2017-07-07 | 郑州大学 | The LSD1 of triazole containing pyrimido inhibitor, its preparation method and application |
-
2018
- 2018-08-03 BR BR112020000827-3A patent/BR112020000827A2/en unknown
- 2018-08-03 JP JP2020505367A patent/JP2020529995A/en active Pending
- 2018-08-03 WO PCT/EP2018/071120 patent/WO2019025588A1/en unknown
- 2018-08-03 MX MX2020001323A patent/MX2020001323A/en unknown
- 2018-08-03 AU AU2018309372A patent/AU2018309372A1/en active Pending
- 2018-08-03 KR KR1020207006287A patent/KR20200036920A/en active IP Right Grant
- 2018-08-03 CA CA3071804A patent/CA3071804A1/en active Pending
- 2018-08-03 SG SG11202000077RA patent/SG11202000077RA/en unknown
- 2018-08-03 CN CN201880050319.1A patent/CN110996949A/en active Pending
- 2018-08-03 EP EP18748921.6A patent/EP3661510A1/en active Pending
- 2018-08-03 US US16/635,704 patent/US20200323828A1/en not_active Abandoned
-
2020
- 2020-01-16 IL IL272092A patent/IL272092A/en unknown
- 2020-01-28 PH PH12020500211A patent/PH12020500211A1/en unknown
- 2020-01-31 MX MX2023009388A patent/MX2023009388A/en unknown
-
2023
- 2023-08-24 JP JP2023136283A patent/JP2023159354A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL272092A (en) | 2020-03-31 |
KR20200036920A (en) | 2020-04-07 |
US20200323828A1 (en) | 2020-10-15 |
MX2020001323A (en) | 2020-03-20 |
PH12020500211A1 (en) | 2020-10-19 |
AU2018309372A1 (en) | 2020-01-30 |
CA3071804A1 (en) | 2019-02-07 |
RU2020109167A3 (en) | 2022-02-10 |
EP3661510A1 (en) | 2020-06-10 |
RU2020109167A (en) | 2021-09-03 |
JP2020529995A (en) | 2020-10-15 |
BR112020000827A2 (en) | 2020-07-21 |
JP2023159354A (en) | 2023-10-31 |
CN110996949A (en) | 2020-04-10 |
MX2023009388A (en) | 2023-08-23 |
WO2019025588A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202000077RA (en) | Methods of treating behavior alterations | |
SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201808709VA (en) | T cell receptors | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
SG11201900400QA (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
SG11201900501RA (en) | Cannabis composition | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof |